Enanta Pharmaceuticals Inc

ENTANASDAQ · USD
10.99USD0.00 (-1.88%)
325

Enanta Pharmaceuticals Inc (ENTA) Covered Calls

Enanta Pharmaceuticals Inc trades in the Biotechnology industry with an IV Rank of 62.30%, average versus the past year. ENTA's highest covered call setup is the $12.50 strike expiring Dec 18, 2026, sorted by theoretical annualized return. It's 13.74% out of the money with 35 days to expiration, a 16.47% return until expiration, and a 171.75% theoretical annualized return. Across the setups shown, annualized returns run from 171.75% to 171.75% at strikes between $12.50 and $12.50, with 35 to 35 days to expiration, as of Nov 13, 2026.

Read more

Running ENTA covered calls helps you generate income from Enanta Pharmaceuticals Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ENTA covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If ENTA stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ENTA covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ENTA covered call is worth writing.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

2026-12-183512.5013.740.300.60181.0016.47171.75-2.73+0.32180.30

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank62.30% Moderate
  • Market cap (M$)320
  • 52 weeks high-35.92%
  • 52 weeks low9.35%
  • Analyst recommendationStrong Buy
    1.17
  • Target price$21.83
    98.64% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-16
  • P/E—
  • Future P/E—
  • EPS (ttm)-2.41
  • EPS growth next 5 years11.43%

As of Nov 13, 2026